Buchumschlag

Attenuation of adverse cardiac effects in prednisolone-treated δ-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism

We have tested the hypothesis that the adverse effects of glucocorticoids in the δ-sarcoglycan-deficient (Sgcd-null) mouse are due to additional mineralocorticoid effects. We investigated the effects of spironolactone, an unselective mineralocorticoid-receptor antagonist, on in vivo cardiac haemodyn...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bauer, Ralf (VerfasserIn) , Blain, Alison (VerfasserIn) , Greally, Elizabeth (VerfasserIn) , Lochmüller, Hanns (VerfasserIn) , Bushby, Kate (VerfasserIn) , MacGowan, Guy A. (VerfasserIn) , Straub, Volker (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2010
In: Neuromuscular disorders
Year: 2010, Jahrgang: 20, Heft: 1, Pages: 21-28
ISSN:1873-2364
DOI:10.1016/j.nmd.2009.10.003
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.nmd.2009.10.003
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0960896609006543
Volltext
Verfasserangaben:Ralf Bauer, Alison Blain, Elizabeth Greally, Hanns Lochmüller, Kate Bushby, Guy A. MacGowan, Volker Straub
Beschreibung
Zusammenfassung:We have tested the hypothesis that the adverse effects of glucocorticoids in the δ-sarcoglycan-deficient (Sgcd-null) mouse are due to additional mineralocorticoid effects. We investigated the effects of spironolactone, an unselective mineralocorticoid-receptor antagonist, on in vivo cardiac haemodynamics, cardiomyocyte damage and fibrosis in prednisolone treated Sgcd-null mice. Oral spironolactone given to 8-week-old Sgcd-null non-steroid treated mice had beneficial effects on systolic function by improving myocardial contractility when assessed by pressure-volume loops. Given in combination with prednisolone, spironolactone prevented steroid-induced deterioration of cardiac haemodynamics and acute sarcolemmal damage but not cardiac fibrosis. This study demonstrates the beneficial effects of oral spironolactone on cardiac haemodynamics in Sgcd-null mice and its ability to prevent some of the adverse effects of glucocorticoids.
Beschreibung:Accepted 5 October 2009
Gesehen am 08.12.2022
Beschreibung:Online Resource
ISSN:1873-2364
DOI:10.1016/j.nmd.2009.10.003

Ähnliche Einträge